Valuation: argenx SE

Market Cap 64.17B 54.98B 51.52B 47.06B 88.81B 6,117B 89.69B 608B 237B 3,086B 241B 236B 10,221B P/E 2026 *
36.6x
P/E 2027 * 29.5x
Enterprise Value 58.92B 50.49B 47.31B 43.21B 81.55B 5,617B 82.36B 558B 217B 2,834B 221B 216B 9,385B EV / Sales 2026 *
9.48x
EV / Sales 2027 * 7.35x
Free-Float
99.98%
Yield 2026 *
0.04%
Yield 2027 * 0.08%

Last Transcript: argenx SE

1 day+1.84%
1 week+2.03%
Current month+20.19%
1 month+13.37%
3 months+28.98%
6 months+37.33%
Current year+24.92%
1 week 858.4
Extreme 858.4
903
1 month 717.4
Extreme 717.4
903
Current year 568.4
Extreme 568.4
903
1 year 568.4
Extreme 568.4
903
3 years 271
Extreme 271
903
5 years 224.1
Extreme 224.1
903
10 years 12.5
Extreme 12.5
903
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+2.03%+49.58%+90.67% 64.17B
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-2.68%+6.05%+55.73%+12.27% 27.33B
-0.30%+4.37%+39.47%-14.65% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
0.00%+0.10%+7.91%+542.94% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
+2.48%+1.11%+329.16%+218.45% 12.55B
Average +1.07%+4.13%+86.71%+199.58% 30.09B
Weighted average by Cap. +1.37%+3.22%+67.09%+158.07%

Financials

2026 *2027 *
Net sales 6.22B 5.33B 4.99B 4.56B 8.6B 593B 8.69B 58.88B 22.92B 299B 23.34B 22.83B 990B 7.69B 6.59B 6.17B 5.64B 10.64B 733B 10.74B 72.79B 28.34B 370B 28.86B 28.23B 1,224B
Net income 1.87B 1.6B 1.5B 1.37B 2.59B 178B 2.61B 17.71B 6.89B 89.92B 7.02B 6.87B 298B 2.49B 2.13B 2B 1.83B 3.45B 238B 3.48B 23.6B 9.19B 120B 9.35B 9.15B 397B
Net Debt -5.25B -4.5B -4.21B -3.85B -7.26B -500B -7.33B -49.69B -19.34B -252B -19.7B -19.27B -836B -7.65B -6.56B -6.14B -5.61B -10.59B -729B -10.7B -72.47B -28.21B -368B -28.73B -28.1B -1,219B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-26 896.40 +1.96% 7,052
26-08-25 €879.20 +1.74% 41,490
26-08-24 €864.20 -4.19% 85,274
26-08-21 €902.00 +1.90% 87,899
26-08-20 €885.20 +0.87% 58,507
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1,026.02USD
Average target price
1,095.01USD
Spread / Average Target
+6.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock